Alnylam Pharmaceuticals Inc
NASDAQ: ALNY
$246.80
-$1.99 (-0.8%)
Closing Price on November 21, 2024
ALNY Articles
Wednesday's top analyst upgrades, downgrades and initiations include Amarin, Baker Hughes, Canopy Growth, Home Depot, Intelsat, Johnson & Johnson, Replimune, Schlumberger and Transocean.
Published:
Last Updated:
Alnylam Pharma and Regeneron Pharma shares dipped on Monday despite announcing a collaboration to discover, develop and commercialize new RNA interference therapeutics for a broad range of diseases.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Monday included Akamai, Dollar Tree, Hasbro, Intel, Mylan, Netflix and Papa John's.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Tuesday include Broadcom, CBS, Etsy, Illumina, PulteGroup, SeaWorld, Wynn Resorts and Zillow.
Published:
Last Updated:
Here is a 24/7 Wall St. calendar with a few of the biggest biotech and pharmaceutical companies expecting clinical trial and FDA updates in April.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include Accenture, American Expresss, Cognizant Technology Solutions, FireEye, Mastercard, PayPal, Verizon and Visa.
Published:
Last Updated:
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates for the rest of March.
Published:
Last Updated:
Jefferies has put together a list of 10 biotech companies that could have developments coming up in the next two weeks to start the year.
Published:
Last Updated:
With 2017 nearing an end, it is important to consider just what has happened. 24/7 Wall St. has screened 50 stocks that have risen 100% or more (some far more) in 2017.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Monday include AMD, Chevron, GM, Intel, Merck, Nokia and Under Armour.
Published:
Last Updated:
courtesy of Jon OggStocks were indicated to open higher on Monday after hitting all-time highs the prior week. The one trend that has been proven time after time in this eight-year bull market is...
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include Axovant, Carnival, Micron Technology, Nike, SunPower, Vivint Solar and Walgreens.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Thursday include AMD, Biogen, Capital One, Intuit, Jinko Solar, Micron Technology, Albermarle and Alnylam Pharmaceuticals.
Published:
Last Updated:
Alnylam Pharmaceuticals saw its shares make a handy gain on Wednesday after the firm gave an update on its late-stage trial in patients with hereditary ATTR amyloidosis with polyneuropathy.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Tuesday include Alibaba, BHP Billiton, Cintas, Monsanto, Schlumberger, Shopify, Hess and Western Digital.
Published:
Last Updated: